Detection of p53 Autoantibodies in Sera of Gastric Cancer Patients and Their Prognostic Relevance

P. Würl Clinic of General Surgery, Institute of Pathology, and Institute of Pathological Biochemistry, Martin Luther University Halle-Wittenberg, Halle/Saale, Germany

F. Weigmann Clinic of General Surgery, Institute of Pathology, and Institute of Pathological Biochemistry, Martin Luther University Halle-Wittenberg, Halle/Saale, Germany

A. Meye Clinic of General Surgery, Institute of Pathology, and Institute of Pathological Biochemistry, Martin Luther University Halle-Wittenberg, Halle/Saale, Germany

M. Fittkau Clinic of General Surgery, Institute of Pathology, and Institute of Pathological Biochemistry, Martin Luther University Halle-Wittenberg, Halle/Saale, Germany

U. Rose Clinic of General Surgery, Institute of Pathology, and Institute of Pathological Biochemistry, Martin Luther University Halle-Wittenberg, Halle/Saale, Germany

D. Berger Clinic of General Surgery, Institute of Pathology, and Institute of Pathological Biochemistry, Martin Luther University Halle-Wittenberg, Halle/Saale, Germany

F. W. Rath Clinic of General Surgery, Institute of Pathology, and Institute of Pathological Biochemistry, Martin Luther University Halle-Wittenberg, Halle/Saale, Germany

H. Dralle Clinic of General Surgery, Institute of Pathology, and Institute of Pathological Biochemistry, Martin Luther University Halle-Wittenberg, Halle/Saale, Germany

H. Taubert Clinic of General Surgery, Institute of Pathology, and Institute of Pathological Biochemistry, Martin Luther University Halle-Wittenberg, Halle/Saale, Germany

show all

Abstract

Background: Changes in the p53 gene product can be immunogenic and enable the formation of p53 serum antibodies (p53ab), detectable in patients with different cancer types. So far, there have been no reports describing the detectability of p53ab in gastric cancer patients. Methods: We investigated the presence of p53ab and their clinical relevance in a cohort of 74 gastric cancer patients, using an enzyme-linked immunosorbent assay system. Results: In our investigation 20.3% of all patients (15 of 74) and 46.9% of the patients with immunohistochemically (IHC) p53-positive tumors (15 of 32) showed detectable p53ab in serum. All p53ab-positive patients had IHC p53-positive tumors. We have found a significant correlation of p53ab with a higher tumor stage (P = 0.002) and also with a poor prognosis of survival (P = 0.04). Conclusion: We have shown that in gastric cancer patients p53ab are also detectable and that p53ab positivity is a predictor of an unfavorable prognosis.

Key Words:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Detection of p53 Autoantibodies in Sera of Gastric Cancer Patients and Their Prognostic Relevance

Information for

Open access

Opportunities

Help and information

Detection of p53 Autoantibodies in Sera of Gastric Cancer Patients and Their Prognostic Relevance

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature